These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8654625)

  • 1. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
    Paoletti AM; Serra GG; Cagnacci A; Vacca AM; Guerriero S; Solla E; Melis GB
    Fertil Steril; 1996 Apr; 65(4):707-10. PubMed ID: 8654625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
    Pierce SJ; Gazvani MR; Farquharson RG
    Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
    Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
    Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of physical training on bone mineral density in women with endometriosis treated with GnRH analogs: a pilot study.
    Bergström I; Freyschuss B; Jacobsson H; Landgren BM
    Acta Obstet Gynecol Scand; 2005 Apr; 84(4):380-3. PubMed ID: 15762970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
    Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
    Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study on the effectiveness and safety of combined laparoscopy and gonadotropin-releasing hormone agonist in the treatment of endometriosis].
    Song JH; Lu H; Zhang J; Li B
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):584-8. PubMed ID: 24199923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
    Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
    Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
    Marshall LA; Cain DF; Dmowski WP; Chesnut CH
    Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate].
    Suzuki Y; Aikawa K; Oishi Y; Yamazaki H; Onishi T; Suzuki M; Kobari T; Endo K; Yanada S; Kato N; Yoshino Y; Wada T; Ueda M; Takasaka S; Akazawa K
    Nihon Hinyokika Gakkai Zasshi; 1998 Dec; 89(12):961-6. PubMed ID: 9990228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis.
    Compston JE; Yamaguchi K; Croucher PI; Garrahan NJ; Lindsay PC; Shaw RW
    Bone; 1995 Feb; 16(2):261-7. PubMed ID: 7756056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.
    Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L
    Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
    Perry CM; Brogden RN
    Drugs; 1996 Feb; 51(2):319-46. PubMed ID: 8808170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
    Matsuo H
    Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.